top of page
The Only CDK4 & 6 Inhibitor Approved Across HR+, HER2- MBC
Tue, Mar 19
|Mistral
This program will present efficacy and safety data for Verzenio, a CDK4 & 6 inhibitor approved in combination with fulvestrant, in combination with an Al, and as a single agent for HR+, HER2- advanced or MBC.
Registration is Closed
See other events
Time & Location
Mar 19, 2019, 6:00 PM
Mistral, 223 Columbus Ave, Boston, MA 02116, USA
Guests
About The Event
Speaker
Yelena Novik, MD
Associate Professor Medical Oncology
NYU Langone
Program Description
This program will present efficacy and safety data for Verzenio, a CDK4 & 6 inhibitor approved in combination with fulvestrant, in combination with an Al, and as a single agent for HR+, HER2- advanced or MBC.
bottom of page